Where does Syntis Bio's cap table come from?

Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Syntis Bio's 3 recorded funding rounds.

Premier Alternatives

Syntis Bio

Boston, MA · Founded 2022 · Privately Held (backing)

Developer of late-stage preclinical drugs designed for oral therapy for obesity, diabetes, and rare diseases. Syntis Bio is based in Boston, MA and was founded in 2022. It was valued at $67 million at its early-stage round in Jun 2025, the last priced event on record. It has raised $48.4 million across 3 recorded rounds; the latest was a $25 million early-stage round in Jun 2025.

PMV mark · valuation

$67.0M

Oct 2026

Priced at

its early-stage round

Jun 2025

Total raised

$48.4M

Last round

Early Stage VC

Jun 2025

Cap table — not yet on record

Syntis Bio's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.

Pro members can request priority coverage with a 48-hour turnaround.

Free account

More of Syntis Bio with a free account

·The complete investor list: 12 names
·Watch Syntis Bio: the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

Frequently asked about Syntis Bio

Where does Syntis Bio's cap table come from?: Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Syntis Bio's 3 recorded funding rounds.